Clinical Characteristics and Treatment of Chest Tightness Variant Asthma

• Inhaled corticosteriod/long-acting beta-agonist plus Montelukast (Drug): Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
• Inhaled corticosteriod/long-acting beta-agonist only (Drug): Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma

Primary outcomes

• Asthma control questionnaire (ACQ) [Change from baseline intervention therapy at 3 months]: Scores of asthma control questionnaire (ACQ)

Secondary outcomes

• Forced expiratory volume in one second [Change from baseline intervention therapy at 3 months]: Value of forced expiratory volume in one second
• Airway responsiveness [Change from baseline intervention therapy at 3 months]: Value of airway responsiveness
• Peak expiratory flow [Change from baseline intervention therapy at 3 months]: Value of peak expiratory flow
• Asthma quality of life questionnaire [Change from baseline intervention therapy at 3 months]: Scores of asthma quality of life questionnaire
• Acute asthma episode [Change from baseline intervention therapy at 3 months]: Numbers of acute asthma episode
• Numbers of emergency or hospitalization [Change from baseline intervention therapy at 3 months]: Numbers of emergency or hospitalization

Sex: All, ages: 14 Years to 80 Years

Inclusion Criteria:

1. all subjects agreed to participate, understand the project, observe the use of drugs, agree to follow-up, and signed informed consent;
2. the age of more than 14 and less 80 years old, gender and ethnicity are not limited;
3. the duration time was more than 6 months,and chest tightness was the only complaint, without breathing, short of breath, chronic cough;
4. no wheezing;
5. a diagnosis of asthma supported by one or more other characteristics:

   * bronchial provocation test positive;
   * improvement in forced expiratory volume at one second (FEV1) of more than 12% and 200 mL after inhaled salbutamol;
   * variability in diurnal peak expiratory flow (PEF) of more than 10% for one day during one week.
6. bronchodilator and glucocorticoid treatment is effective;
7. exclude the following diseases by the corresponding doctors: coronary heart disease, myocarditis, heart failure, gastroesophageal reflux disease(GERD), neuromuscular disease, and mental disease.

Exclusion Criteria:

1. can not cooperate with related inspection or for other reasons;
2. patients with chronic obstructive pulmonary disease, interstitial pneumonia, active tuberculosis, community acquired pneumonia, lung cancer, bronchiectasis, cor pulmonale, pulmonary embolism, and accompanied with serious systematic disease (such as coronary heart disease, myocarditis, heart failure, gastroesophageal reflux disease, neuromuscular disease, etc);
3. history of drug abuse, alcohol abuse or anesthesia or with a history of mental illness (schizophrenia, obsessive-compulsive disorder, depression) and against personality, motivation, suspicious, or other emotional or mental issues that may affect participation in the study;
4. taking part in other drug clinical trial project, or drop out less than 3 months;
5. during pregnancy, lactation women;
6. obvious abnormal of High Resolution CT.